Back to Trades
Total Value
$135.3K
Net $65.8K sold
Filing Date
Jul 10, 2026
1 transaction
Sales
$65.8K
1 transaction
Trade Summary
On Jul 9, 2026, Rodman David Malcom, Chief Medical Officer, sold $135.3K of Mineralys Therapeutics, Inc. (MLYS) across 1 transaction. The filing covers Common Stock and reflects net selling of $65.8K. Reported prices ranged from $16.00 to $30.30. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Mineralys Therapeutics, Inc.
- Ticker Symbol
- MLYS
- CIK
- 0001933414
Insider Information
- Role
- Chief Medical Officer
- Location
- RADNOR, PA
Filing Details
- Filing Date
- Jul 10, 2026
- Transaction Date
- Jul 9, 2026
- Accession Number
- 0001672659-26-000033
- Form Type
- 4
- Net Trading Amount
- -$65.8K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 9, 2026 | Common Stock | 2,171 | $16.00 | Exercise | $34.7K |
| Jul 9, 2026 | Common Stock | 2,171 | $30.30 | Sale | $65.8K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 9, 2026 | MLYS derivative | 2,171 | $16.00 | Exercise | $34.7K |
Want live alerts when Rodman David Malcom trades again?
Download Insider Trades to track MLYS, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
- (F2)This balance includes 638 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.
- (F3)The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.